CRS-207 With Keytruda in Previously Treated Pleural Mesothelioma
Status: No Longer Recruiting
Type: Pleural Mesothelioma
Immunotherapy works with your immune system to fight cancer. This trial uses two top immunotherapy drugs to treat pleural mesothelioma.
Immunotherapy as a Second Line Treatment
The goal of this study is to evaluate whether a combination of two immunotherapy drugs, CRS-207 with Keytruda (pembrolizumab), is safe and effective. This trial is for adults with pleural mesothelioma who have failed prior anti-cancer treatment.
What to Expect
CRS-207 Vaccine – In an ongoing CRS-207 trial, 94 percent of pleural mesothelioma patients achieved disease control. CRS-207 is a type of cancer vaccine. It was created from a virus to induce an immune response to cancer.
Keytruda (pembrolizumab) – Keytruda reduced cancer size in 14 out of 25 pleural mesothelioma patients in an ongoing trial according to a recent report. Keytruda works by helping the immune system recognize and attack cancer cells.
Second Line Treatment -This trial is for patients who have already had chemotherapy treatment without success. Researchers hope this combination of immunotherapies will be an effective second line treatment.
Get Help Enrolling in This Trial
Reasons to consider this trial:
- Receive innovative immunotherapies
- Get treated by top mesothelioma doctors
- Gain an option after failed chemotherapy
CRS-207 & Keytruda Treatment Plan
Patients will receive their treatment in 3 week cycles. For the first 4 cycles, patients will receive both CRS-207 and Keytruda every three weeks. After the first 4 cycles, patients will receive Keytruda every 3 weeks but CRS-207 every 6 weeks.
1Keytruda is administered by IV (intravenous infusion) for 30 minutes.
2CRS-207 is administered by IV for 1 hour.
For the first treatment cycle, patients will receive the treatments on separate days. If the treatments are well tolerated in the first cycle, patients can receive both in one day.
Drugs in This Trial
Keytruda (pembrolizumab, MK-3475)
Keytruda is an immunotherapy drug. Some cancers are able to hide from the immune system, but Keytruda helps the immune system recognize cancer so that it can attack. Keytruda is FDA approved for several cancers, including some types of lung cancer. Researchers hope that Keytruda will eventually be approved for pleural mesothelioma treatment.
Keytruda blocks the PD-1 receptor on T cells. T cells are the part of the immune system responsible for fighting infections and diseases. Some cancer cells release PD-L1, a protein that is absorbed by the PD-1 receptor. PD-L1 can trick the T cell into ignoring cancer cells instead of attacking them. Keytruda blocks the PD-1 receptor, allowing the T cells to identify and attack the cancer cells.
CRS-207 is an altered form of a the Listeria virus. Listeria is a bacteria that sometimes contaminates food. The goal of CRS-207 is to induce an immune response. Researchers alter the virus so that it is no longer infectious and so that it expresses mesothelin, an antigen that is often expressed by mesothelioma tumors.
The immune system sees the CRS-207 virus and responds to it. In this way, CRS-207 trains the immune system to target mesothelin. Once the immune system begins targeting mesothelin, it will recognize the cancer cells expressing it as a threat and attack them.
Who Is This Trial For?
This trial is for pleural mesothelioma patients looking for a second line treatment after their first treatment failed. Patients’ cell type should be epithelial or biphasic as long it is at least 50% epithelial cell type. They must have previously been treated with chemotherapy, including pemetrexed and a platinum based drug, without success.
UCSF Comprehensive Cancer Center
San Francisco, California, 94115
Principal Investigator: Thierry M Jahan, MD
H. Lee Moffitt Cancer Center
Tampa, Florida, 33602
Principal Investigator: Tawee Tanvetyanon, MD
NIH National Cancer Institute
Bethesda, Maryland, 20892
Principal Investigator: Raffit Hassan, MD
Laura & Isaac Perlmutter Cancer at NYU Langone
New York, New York, 10016
Principal Investigator: Leena Gandhi, MD, PhD
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104
Principal Investigator: Evan Alley, MD
Get Enrolled in This Trial
Both immunotherapy drugs in this trial have had impressive results in previous mesothelioma clinical trials. Pleural mesothelioma patients who have undergone chemotherapy unsuccessfully should consider this trial as a second line treatment. Get more information and get connected to this trial.